Last reviewed · How we verify

Investigational aQIVc

Seqirus · Phase 3 active Biologic

Investigational aQIVc is a Influenza vaccine (quadrivalent, cell-based) Biologic drug developed by Seqirus. It is currently in Phase 3 development for Seasonal influenza prevention in adults.

aQIVc is a cell-based quadrivalent influenza vaccine designed to provide broader and more durable immune protection against multiple influenza strains.

aQIVc is a cell-based quadrivalent influenza vaccine designed to provide broader and more durable immune protection against multiple influenza strains. Used for Seasonal influenza prevention in adults.

At a glance

Generic nameInvestigational aQIVc
SponsorSeqirus
Drug classInfluenza vaccine (quadrivalent, cell-based)
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

aQIVc uses recombinant technology to produce influenza virus-like particles (VLPs) representing four influenza strains (H1N1, H3N2, and two B lineages) in cultured animal cells rather than eggs. This cell-based manufacturing approach may improve vaccine yield, reduce production time, and potentially enhance immunogenicity compared to traditional egg-based vaccines.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Investigational aQIVc

What is Investigational aQIVc?

Investigational aQIVc is a Influenza vaccine (quadrivalent, cell-based) drug developed by Seqirus, indicated for Seasonal influenza prevention in adults.

How does Investigational aQIVc work?

aQIVc is a cell-based quadrivalent influenza vaccine designed to provide broader and more durable immune protection against multiple influenza strains.

What is Investigational aQIVc used for?

Investigational aQIVc is indicated for Seasonal influenza prevention in adults.

Who makes Investigational aQIVc?

Investigational aQIVc is developed by Seqirus (see full Seqirus pipeline at /company/seqirus).

What drug class is Investigational aQIVc in?

Investigational aQIVc belongs to the Influenza vaccine (quadrivalent, cell-based) class. See all Influenza vaccine (quadrivalent, cell-based) drugs at /class/influenza-vaccine-quadrivalent-cell-based.

What development phase is Investigational aQIVc in?

Investigational aQIVc is in Phase 3.

What are the side effects of Investigational aQIVc?

Common side effects of Investigational aQIVc include Injection site pain or erythema, Myalgia, Headache, Fatigue.

Related